天津医药

天津医药 ›› 2021, Vol. 49 ›› Issue (11): 1222-1227.doi: 10.11958/20211261

• 综述 • 上一篇    下一篇

单克隆抗体药物治疗视神经脊髓炎谱系疾病的临床试验研究进展

刘晔，孟德旺，杨贵莉，孙莉   

  1. 1天津医科大学总医院神经内科，天津市神经病学研究所，教育部“中枢神经系统创伤修复与再生”重点实验室，天津市“神经损伤变异与再生”重点实验室（邮编300052）；2天津市胸科医院病案质检科
  • 收稿日期:2021-05-26 修回日期:2021-07-22 出版日期:2021-11-15 发布日期:2021-11-19
  • 基金资助:
    国家自然科学基金青年项目（81601039）；国家自然科学基金面上项目（82071389）；天津市自然科学基金（20JCQNJC00460）

Progress in clinical trials of monoclonal antibody therapy for neuromyelitis optica pedigree diseases

LIU Ye, MENG De-wang, YANG Gui-li, SUN Li   

  1. 1 Department of Neurology, Tianjin Medical University General Hospital, Tianjin Neurological Institute, Key Laboratory of Post-trauma Neuro-repair and Regeneration in Central Nervous System, Ministry of Education; Tianjin Key Laboratory of Injuries, Variations and Regeneration of Nervous System, Tianjin 300052, China; 2 Department of Medical Record Quality Control, Tianjin Chest Hospital
  • Received:2021-05-26 Revised:2021-07-22 Published:2021-11-15 Online:2021-11-19

PDF (PC)

2875

摘要： 视神经脊髓炎谱系疾病（NMOSD）是一种体液免疫介导的中枢神经系统自身免疫性疾病，以脊髓和视神经的炎性脱髓鞘病变为特征，可导致瘫痪和失明。其治疗除传统的免疫抑制剂外，还有B细胞靶向的利妥昔单抗及伊比利珠单抗，抑制白细胞介素-6受体的托珠单抗和沙妥珠单抗，阻断补体介导的细胞毒性和继发性炎症的依库珠单抗等新型靶向药物。就治疗NMOSD的单克隆抗体靶向药物的作用机制、疗效、不良反应及其研究进展予以综述。

关键词: 视神经脊髓炎, 水通道蛋白质4, 抗体, 单克隆, 利妥昔单抗, 临床试验, 分子靶向治疗

Abstract: Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system mediateNeuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system mediated by humoral immunity. It is characterized by inflammatory demyelination of the spinal cord and optic nerve, which may lead to paralysis and blindness. In addition to traditional immunosuppressants, more and more new drugs are used in the treatment of NMOSD, such as rituximab and inebilizumab targeting B cells, tocilizumab and satralizumab inhibiting interleukin-6 receptor and eculizumab blocking complement mediated cytotoxicity and secondary inflammation. In recent years, the results of several randomized clinical trials of these monoclonal antibody drugs have been published. This paper will review the research progress of these targeted drugs in the treatment of NMOSD from the aspects of the mechanism of action, efficacy and adverse reactions.

Key words: neuromyelitis optica, aquaporin 4, antibodies, monoclonal, rituximab, clinical trial, molecular targeted therapy